Last reviewed · How we verify
Slow-tapering glucocorticoids + Inebilizumab
Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), combined with slow-tapering glucocorticoids to suppress pathogenic B cell and autoimmune responses.
Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), combined with slow-tapering glucocorticoids to suppress pathogenic B cell and autoimmune responses. Used for Systemic lupus erythematosus (SLE), Autoimmune conditions responsive to B cell and pDC modulation.
At a glance
| Generic name | Slow-tapering glucocorticoids + Inebilizumab |
|---|---|
| Sponsor | Tianjin Medical University General Hospital |
| Drug class | Monoclonal antibody + Glucocorticoid combination |
| Target | BDCA-2 (CD320) on plasmacytoid dendritic cells; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Autoimmune disease |
| Phase | Phase 3 |
Mechanism of action
Inebilizumab binds to BDCA-2 (blood dendritic cell antigen 2) on plasmacytoid dendritic cells, reducing their activation and type I interferon production, which drives autoimmune disease. The combination with glucocorticoids provides additional immunosuppression through corticosteroid mechanisms (NF-κB inhibition, T cell suppression) while allowing gradual tapering to minimize long-term steroid toxicity.
Approved indications
- Systemic lupus erythematosus (SLE)
- Autoimmune conditions responsive to B cell and pDC modulation
Common side effects
- Infection (including opportunistic)
- Infusion reactions
- Glucocorticoid-related adverse effects (hyperglycemia, osteoporosis, mood changes)
- Immunosuppression-related complications
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: